Early clinical trials presented at the 2017 American Society of Clinical Oncology (ASCO) annual meeting showed that CAR-T cell therapy using B cell maturation antigen (BCMA) as a biomarker could prevent the development of multiple myeloma. This evidence concerns the gene TNFRSF17 and AL amyloidosis.